Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.
作者信息
Raanani Pia, Goldman John M, Ben-Bassat Isaac
机构信息
The Chaim Sheba Medical Center, Tel-Hashomer, Israel.
出版信息
J Clin Oncol. 2002 Feb 1;20(3):869-70. doi: 10.1200/JCO.2002.20.3.869.
PMID:11821474
Abstract
摘要
相似文献
1
Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.
J Clin Oncol. 2002 Feb 1;20(3):869-70. doi: 10.1200/JCO.2002.20.3.869.
2
Hypopigmentation from imatinib mesylate (Gleevec).
J Pediatr Hematol Oncol. 2004 Mar;26(3):214. doi: 10.1097/00043426-200403000-00016.
3
Imatinib mesylate induced skin hypopigmentation.
J Assoc Physicians India. 2007 Jul;55:527.
4
Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
Pol Arch Med Wewn. 2013;123(5):251-2.
5
Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
Hong Kong Med J. 2014 Oct;20(5):464.e2. doi: 10.12809/hkmj134084.
6
Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia.
Leuk Lymphoma. 2012 Nov;53(11):2310-1. doi: 10.3109/10428194.2012.680452. Epub 2012 Apr 30.
7
Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.
J Clin Oncol. 2003 Jan 1;21(1):172-3. doi: 10.1200/JCO.2003.01.052.
8
Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia.
Hematol Oncol Stem Cell Ther. 2009;2(2):358-61. doi: 10.1016/s1658-3876(09)50026-x.
9
Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
Am J Hematol. 2005 May;79(1):79-80. doi: 10.1002/ajh.20274.
10
Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
Ann Oncol. 2004 Feb;15(2):358-9. doi: 10.1093/annonc/mdh068.
引用本文的文献
1
Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.
J Am Acad Dermatol. 2017 Nov;77(5):902-910.e2. doi: 10.1016/j.jaad.2017.06.044. Epub 2017 Sep 14.
2
Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.
Biologics. 2010 Dec 2;4:315-23. doi: 10.2147/BTT.S5775.
3
Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor.
J Korean Med Sci. 2005 Jun;20(3):512-5. doi: 10.3346/jkms.2005.20.3.512.
4
Selective effect of imatinib on serum IgM in a patient with CML.
Int J Hematol. 2004 Nov;80(4):381-2. doi: 10.1532/ijh97.04105.
5
Hypopigmentation in an African patient treated with imatinib mesylate: a case report.
J Natl Med Assoc. 2003 Aug;95(8):722-4.
Zotero 插件